摘要: Through rapid advancement of genomics by Next Generation Sequencing (NGS) and proteomics Mass Spectrometry (MS) technologies innovative sampling bioinformatic strategies a new era personalized medicine is upon us. Secreted proteins play an important role in tumorigenesis through cell growth, migration, invasion, angiogenesis. As such, the measure all secreted or shed proteins, referred to as “secretomics”, could be invaluable terms identifying early pharmacological physiological biomarkers associated with cancer diagnosis progression, therapeutic response and/or resistance even novel druggable protein targets. Most FDA-approved are measured standard immunoassay. There emerging rationale that our understanding complexity tumor biology microenvironment increases at accelerated rate, antiquated assays limited detecting single markers may have narrow applicability utility clinical setting relevancy disease diversity given patient population.